Literature DB >> 12834809

Activation of ERK1/2 by platelet-activating factor receptor is independent of receptor internalisation and G-protein activation.

Zhangguo Chen1, Marek Rola-Pleszczynski, Jana Stankova.   

Abstract

Platelet-activating factor (PAF) is a potent pro-inflammatory phospholipid mediator involved in a broad range of physiological and pathophysiological processes. The receptor of PAF (PAFR) is a heptahelical G-protein-coupled receptor. We have shown previously that upon agonist stimulation, PAFR internalised through clathrin-coated vesicles in an arrestin-dependent, but G-protein-coupling-independent manner. In the current report, we demonstrate that PAF stimulates Erk1/2 phosphorylation and: (1). dominant negative mutants of arrestins and dynamin do not influence Erk1/2 activation, (2). hypertonic conditions do not decrease the extent of Erk1/2 phosphorylation, (3). internalisation-deficient and/or G-protein-coupling-deficient mutants of PAFR activate Erk1/2 as efficiently as the wild-type PAFR, and (4). inhibition of epidermal growth factor receptor (EGFR) does not block Erk1/2 activation. Taken together, our results suggest that PAFR-mediated activation of mitogen-activated protein kinases Erk1/2 does not require receptor endocytosis, receptor tyrosine kinase transactivation or G-protein activation. In addition, our studies reveal that PAFR-mediated signals of G-protein activation, receptor internalisation and MAPK activation are differentially regulated by receptor structure and/or conformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834809     DOI: 10.1016/s0898-6568(03)00056-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

1.  Rescue of internalization-defective platelet-activating factor receptor function by EBP50/NHERF1.

Authors:  Denis J Dupré; Marek Rola-Pleszczynski; Jana Stankova
Journal:  J Cell Commun Signal       Date:  2012-08-10       Impact factor: 5.782

2.  Multiple scaffolding functions of {beta}-arrestins in the degradation of G protein-coupled receptor kinase 2.

Authors:  Laura Nogués; Alicia Salcedo; Federico Mayor; Petronila Penela
Journal:  J Biol Chem       Date:  2010-11-16       Impact factor: 5.157

3.  Down-regulation of platelet-activating factor receptor gene expression during focal reversible cerebral ischemia in rats.

Authors:  Xiong Zhang; Xi-Long Pan; Xin-Tong Liu; Shuo Wang; Li-Juan Wang
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 3.996

4.  RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome.

Authors:  Nina Bögershausen; I-Chun Tsai; Esther Pohl; Pelin Özlem Simsek Kiper; Filippo Beleggia; E Ferda Percin; Katharina Keupp; Angela Matchan; Esther Milz; Yasemin Alanay; Hülya Kayserili; Yicheng Liu; Siddharth Banka; Andrea Kranz; Martin Zenker; Dagmar Wieczorek; Nursel Elcioglu; Paolo Prontera; Stanislas Lyonnet; Thomas Meitinger; A Francis Stewart; Dian Donnai; Tim M Strom; Koray Boduroglu; Gökhan Yigit; Yun Li; Nicholas Katsanis; Bernd Wollnik
Journal:  J Clin Invest       Date:  2015-08-17       Impact factor: 14.808

5.  Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis.

Authors:  Matheus Correa-Costa; Vinicius Andrade-Oliveira; Tarcio T Braga; Angela Castoldi; Cristhiane F Aguiar; Clarice S T Origassa; Andrea C D Rodas; Meire I Hiyane; Denise M A C Malheiros; Francisco J O Rios; Sonia Jancar; Niels O S Câmara
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

6.  Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice.

Authors:  Changxin Xu; Ethan C Reichert; Tomoyuki Nakano; Mariah Lohse; Alison A Gardner; Mónica P Revelo; Matthew K Topham; Diana M Stafforini
Journal:  Cancer Res       Date:  2013-01-29       Impact factor: 12.701

7.  Regulation of platelet-activating factor-mediated protein tyrosine phosphatase 1B activation by a Janus kinase 2/calpain pathway.

Authors:  Geneviève Hamel-Côté; Daniel Gendron; Marek Rola-Pleszczynski; Jana Stankova
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.